Conexiant’s news site is now MDSpire News. Learn more
Advertisement
Roving Reporter Asks: How Should We Redefine Value, Access, and Affordability in Cell and Gene Therapy?
IBTV speaks with industry leaders at ASGCT 2026 about new approaches to manufacturing, reimbursement, treatment delivery, and long-term value that could bring cell and gene therapies to more patients
Clinical Report: Rethinking Value, Access, and Affordability in Cell and Gene Therapy
Background
Cell and gene therapies have the potential to alter the treatment landscape for serious diseases. However, high manufacturing costs, complex delivery systems, and uncertain reimbursement models pose barriers to patient access. Addressing these challenges is critical for the integration of these therapies into standard care.
Data Highlights
No numerical data or trial data was provided in the source material.
Key Findings
High manufacturing costs and complex delivery pathways restrict patient access to cell and gene therapies.
Industry leaders advocate for reducing production costs and treating patients earlier in the disease process.
Expanding delivery beyond specialist centers is essential for improving access.
Long-term value assessment of therapies should be prioritized over upfront pricing.
Collaboration among manufacturers, regulators, healthcare systems, payers, and patient advocates is necessary for sustainable access.
Clinical Implications
Healthcare professionals should be aware of the evolving landscape of cell and gene therapies and the importance of collaborative efforts to enhance patient access.
Conclusion
The discussion highlights the need for a comprehensive approach to redefine value and access in cell and gene therapy, ensuring that these transformative treatments become more widely available.
Increases in apnea-hypopnea events were greatest among patients with an elevated baseline index, while evidence supporting mouth taping remained preliminary.
